Bioxyne Enters Costa Rica as First International Cannabis Flower Supplier
Bioxyne enters Costa Rica as first international medicinal cannabis flower supplier
Bioxyne Limited (ASX: BXN), through its wholly owned subsidiary Breathe Life Sciences (BLS), has executed an expanded supply agreement with Remidose LATAM SRL to supply three Dr Watson® cannabis flower SKUs into Costa Rica, marking the first international supply of medicinal cannabis flower into the country’s regulated market. The initial shipment is expected prior to 30 June 2026, with an invoice value set to exceed $500,000.
Key details from the announcement include:
- Three Dr Watson® cannabis flower SKUs covered under the expanded agreement
- Initial shipment value to exceed $500,000, expected before 30 June 2026
- Expansion of the original December 2025 agreement with Remidose, which covered cannabis pastilles for Costa Rica and Panama
- Repeat orders expected, subject to market conditions and regulatory approvals
When big ASX news breaks, our subscribers know first
What this deal means and why Costa Rica matters
A regulated but uncrowded market
Costa Rica represents an early-stage regulated medicinal cannabis market with limited international competition and significant long-term growth potential. Evolving regulatory frameworks and increasing patient access are supporting demand, and Bioxyne has entered ahead of competing international suppliers that are still progressing through local approval pathways.
In a LATAM context, a “regulated medicinal cannabis market” means the government has established a legal framework for the import, distribution, and dispensing of medicinal cannabis products to patients. For international suppliers, this creates a defined pathway to participate, but the framework is still maturing compared to more developed markets such as Germany or Australia.
Being first into a regulated LATAM market carries strategic weight beyond the initial transaction. Early-mover advantages include brand registration priority, a distribution foothold with an established local partner, and the ability to set a regulatory precedent that can be referenced across other jurisdictions in the region. In more mature markets, these positions have already been claimed; in early-stage markets like Costa Rica, they are still available.
From pastilles to flower — how the Remidose relationship evolved
The Bioxyne–Remidose relationship has expanded in scope across a relatively short timeframe, reflecting strong partner alignment:
- December 2025: Initial supply agreement executed, covering cannabis pastilles for distribution into Costa Rica and Panama.
- May 2026: Agreement expanded to include three Dr Watson® cannabis flower SKUs for Costa Rica.
- Future scope: Pastilles confirmed to follow flower into Costa Rica; Panama remains within the agreement’s scope.
The progression from pastilles to flower supply within a matter of months signals that demand on the ground is validating the initial partnership thesis rather than merely sustaining it.
CEO Sam Watson
“We’ve moved from our initial agreement into a broader supply scope in a short period of time, which reflects both the strength of the relationship and the level of demand we’re seeing on the ground.”
The investment case — first-mover position in LATAM’s emerging cannabis markets
A $500,000 shipment is the opening move, not the destination
The initial shipment, with an invoice value exceeding $500,000, is expected to be delivered before 30 June 2026, placing it within the current financial year. Based on current demand forecasts, Bioxyne expects repeat orders to follow, subject to market conditions and regulatory approvals.
Perhaps the most telling indicator of near-term momentum comes from Remidose’s own Managing Director, who noted that initial stock allocations may be committed before the product has even reached the market.
Remidose Managing Director Michael Mayne
“Early indications of demand have been exceptionally strong – to the point where initial stock may well be fully committed before product even arrives in market.”
BLS’s platform makes this scalable
BLS’s structural credentials underpin its ability to enter regulated international markets efficiently. Key capabilities include:
- GMP-licensed manufacturer, wholesaler, importer, and exporter of controlled substances
- Operations across Queensland (Australia), Nagoya (Japan), Scotland (UK), and Prague (Czech Republic)
- Established export capability and regulatory experience cited as enabling early market entry
- Dr Watson® brand owner-registered in the UK, Japan, Australia, and New Zealand, with Costa Rica now added to this footprint
- Raw material sourcing from suppliers across five continents
The Remidose agreement structure, as it currently stands, is summarised below:
| Market | Product | Agreement Stage | Timeline | Notes |
|---|---|---|---|---|
| Costa Rica | Dr Watson® cannabis flower (3 SKUs) | Expanded May 2026 | Shipment before 30 June 2026 | First international supply into market |
| Costa Rica | Cannabis pastilles | Future supply (confirmed in agreement) | TBC | Follows flower supply |
| Panama | Cannabis pastilles | Original December 2025 agreement | TBC | Part of initial Remidose scope |
The next major ASX story will hit our subscribers first
What comes next for Bioxyne in LATAM and beyond
Costa Rica is positioned as the foundation market for a broader LATAM expansion, with Remidose’s existing regional network providing a logical pathway into additional jurisdictions. LATAM and Europe remain the two stated key growth regions for BLS’s GMP supply platform.
Product registration for Costa Rica is described as “well advanced,” representing a near-term catalyst for the business. The overarching strategy is to scale GMP-certified manufacturing and supply across regulated international markets as those frameworks continue to develop.
The investment thesis that emerges from this announcement is reasonably clear. Bioxyne’s combination of GMP manufacturing credentials, an internationally recognised brand in Dr Watson®, and a proven distribution partner in Remidose positions the company to replicate this market-entry model across other LATAM jurisdictions. As CEO Sam Watson stated, being the first to supply branded medicinal cannabis flower into Costa Rica gives the company “the platform to expand into other LATAM jurisdictions as those markets continue to open.”
Get Healthcare Sector-Moving ASX News Before the Market Reacts
Big News Blast delivers FREE breaking ASX healthcare announcements directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market on news like this. Click the “Free Alerts” button to start receiving real-time alerts the moment the next announcement drops.